Strategic Acquisitions, Commercial Collaborations, and New Appointments - Research Report on Solta Medical, Opko Health,

  Strategic Acquisitions, Commercial Collaborations, and New Appointments -
        Research Report on Solta Medical, Opko Health, NuPathe, AcelRx
                 Pharmaceuticals, and Momenta Pharmaceuticals

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, December 19, 2013

NEW YORK, December 19, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Solta
Medical, Inc. (NASDAQ: SLTM), Opko Health, Inc. (NYSE: OPK), NuPathe, Inc.
(NASDAQ: PATH), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), and Momenta
Pharmaceuticals Inc. (NASDAQ: MNTA). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Solta Medical, Inc. Research Report

On December 16, 2013, Solta Medical, Inc. (Solta Medical) announced that it
has entered into a definitive agreement with Valeant Pharmaceuticals
International, Inc. (Valeant), pursuant to which Valeant will acquire all of
the Company's outstanding common stock for $2.92 per share in cash or total
consideration of approximately $250 million. Solta Medical reported that the
acquisition is expected to close in Q1 2014 and to be immediately accretive to
Valeant's cash EPS, once completed. Commenting on the acquisition agreement,
Mark Sieczkarek, Chairman of the Board and Interim CEO of Solta Medical said,
"Our Board of Directors has determined that this all cash offer is in the best
interest of our stockholders. We further believe the acquisition by Valeant
provides the best opportunity for Solta Medical brands and our employees to
achieve their full potential while generating a significant, near term return
for our stockholders." The Full Research Report on Solta Medical, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/c5ec_SLTM

--

Opko Health, Inc. Research Report

On December 16, 2013, Opko Health, Inc. (Opko Health) announced that it has
entered into an agreement to acquire Laboratorio Arama de Uruguay Limitada
(Arama). Opko Health reported that the acquisition is expected to add to its
South American presence in the Mercosur economic region while further
complementing its business activities in Chile, Mexico, and Brazil. Phillip
Frost, M.D., Chairman and CEO of Opko Health, said, "We continue to broaden
our commercial prospects through investments that complement our existing
businesses and bolster the global reach of our robust product pipeline." Frost
continued, "This acquisition will allow Opko to establish a footprint in
Uruguay and facilitate future sales and commercial expansion into neighboring
Argentina. In the near term, Arama provides another platform for the
commercialization of our 4Kscore, a novel panel of biomarkers and associated
algorithm to more accurately detect and grade possible prostate cancers." Opko
Health reported that the transaction is expected to close in January 2014. The
Full Research Report on Opko Health, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.AnalystsCorner.com/r/full_research_report/cd43_OPK

--

NuPathe, Inc. Research Report

On December 16, 2013, NuPathe, Inc. (NuPathe) announced that it has entered
into a definitive agreement with Endo Health Solutions (Endo), under which
Endo will acquire NuPathe for $2.85 per share in cash for a total
consideration of approximately $105 million. In addition to the upfront cash
payment, NuPathe shareholders will receive rights to receive additional cash
payments of up to $3.15 per share if specified net sales of NuPathe's migraine
treatment ZECUITY are achieved over time. Armando Anido, NuPathe CEO,
commented, "Our team has worked very hard to develop products that we believe
will provide significant clinical advantages over current treatments for
patient populations facing diseases of the central nervous system. We believe
this acquisition by Endo will increase the potential for ZECUITY to make a
meaningful difference for patients we have worked so hard to serve." NuPathe
expects the transaction to be completed in early 2014. The Full Research
Report on NuPathe, Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/d5b0_PATH

--

AcelRx Pharmaceuticals, Inc. Research Report

On December 16, 2013, AcelRx Pharmaceuticals, Inc. (AcelRx) announced that it
has entered into a commercial collaboration with Grunenthal GmbH, covering the
territory of the European Union, certain other European countries and
Australia for ZALVISO (previously known as ARX-01) for potential use in pain
treatment within or dispensed by a hospital, hospice, nursing home or other
medically supervised setting. AcelRx reported that its lead program, ZALVISO,
is a drug-device combination product utilizing the opioid agonist sufentanil
formulated in a proprietary sublingual tablet formulation and delivered
through a pre-programmed, non-invasive proprietary delivery device. The
Company said that it will receive an upfront payment of $30 million, and is
eligible to receive approximately $220 million in additional milestone
payments, based upon successful regulatory and product development efforts and
net sales target achievements. The Full Research Report on AcelRx
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/1454_ACRX

--

Momenta Pharmaceuticals Inc. Research Report

On December 12, 2013, Momenta Pharmaceuticals Inc. (Momenta) announced the
appointment of Michael Franken, M.D. as President, Biosimilars Business.
According to the Company, Dr. Franken will oversee the operational management
of biosimilars program, including its collaboration with Baxter International
Inc., strategic planning, P&L responsibility, and other supporting activities.
Commenting on the appointment, Craig Wheeler, Momenta's President and CEO
said, "Michael brings more than 17 years of broad experience to the company,
including a valuable combination of operations skills, market expertise and
business development. With this focus, we will better align our resources and
expertise to create an even stronger collaboration with Baxter to advance this
core business." The Full Research Report on Momenta Pharmaceuticals Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/c334_MNTA

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.